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Abstract
Expression of transgenes is central to forward and reverse genetic analysis in Trypanosoma brucei. The inducible expression
of transgenes in trypanosomes is based on the tetracycline repressor binding to a tetracycline operator to prevent
transcription in the absence of tetracycline. The same inducible system is used to produce double-stranded RNA for RNAi
knockdown of target genes. This study describes a new plasmid pSPR2.1 that drives consistent high-level expression of
tetracycline repressor in procyclic form trypanosomes. A complementary expression plasmid, p3227, was constructed. The
major difference between this and current plasmids is the separation of the inducible transgene and selectable marker
promoters by the plasmid backbone. The plasmid p3227 was able to support inducible expression in cell lines containing
pSPR2.1 as well as the established Lister 427 29-13 cell line. p3666, a derivative of p3227, was made for inducible expression
of stem loop RNAi constructs and was effective for knockdown of DRBD3, which had proved problematic using existing
RNAi plasmids with head-to-head promoters. The plasmid system was also able to support inducible transgene expression
and DRBD3 RNAi knockdown in bloodstream form cells expressing tetracycline repressor from an integrated copy of the
plasmid pHD1313.
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Introduction
The expression of transgenes is central to many investigations of
gene function. Evidence for function can be gained from an
investigation of phenotype after expression of transgene at altered
levels or in cell types in which there is normally no expression. The
transgene can encode the wild type or an altered protein; for
example it may be expressed as a fusion with a fluorescent protein
to investigate sub-cellular localisation or with a tag to enable rapid
identification of interacting proteins. The use of transgenes
encoding mutants that are inactive and have a dominant
phenotype can be particularly informative. The expression of the
transgene can be constitutive or conditional; the latter is essential if
expression of the transgene causes a cessation of proliferation. The
use of transgenes in functional genomics is the basis of reverse
genetics. A second important use of transgenes is in the production
of reporter cell lines for forward genetic screens, an approach that
is best developed in yeast genetics. For example, a cell line that
expresses a fluorescent marker protein can be used in a forward
screen for loss of expression and isolated using fluorescence
activated cell sorting.
Here, a system for tetracycline-inducible transgene expression in
Trypanosoma brucei that is independent of T7 RNA polymerase (T7
RNAP) is described. It is a two-component system: a novel plasmid
for tetracycline repressor (TetR) expression combined with
plasmids for transgene or stem loop RNA expression. The system
shows little clonal variation and can be readily introduced into a
range of cell lines.
A range of plasmids is already available for both constitutive
and inducible expression of transgenes in trypanosomes. The
inducible expression systems invariably use the tetracycline system.
The TetR binds to tetracycline operator (tetO) sites located within
a promoter and prevents transcription; addition of exogenous
tetracycline causes release of TetR and permits transcription. The
EP1 procyclin promoter was the first to be modified to be
tetracycline-inducible [1][2] and expression levels were titred
using a range of tetracycline concentrations. Subsequently the
rRNA promoter was modified to be tetracycline responsive [3].
In trypanosomes, mRNAs are processed by the trans-splicing of
a short exon, called the spliced leader, to the 59 end.
Consequently, it has been possible to achieve high levels of
transcription using T7 RNA polymerase (RNAP): the addition of
the spliced leader results in a mature capped mRNA [4]. Plasmid
systems for tetracycline-inducible T7 RNAP driven expression
of transgenes were amongst the first to be developed [5] and
the same promoters have been used in head to head RNAi
plasmids [6].
In an early set of plasmids exploiting tetracycline-inducible
promoters, the selectable marker gene was placed under the
control of a constitutive promoter downstream of the inducible
transgene, for example pHD437 and derivatives [7] (http://www.
zmbh.uni-heidelberg.de/clayton/vectors.html); this arrangement
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tetracycline was variable [7].
In the second generation plasmids, for example pLEW100 and
derivatives [2] (http://tryps.rockefeller.edu/trypsru2_plasmids.
html), the tetracycline-inducible EP1 promoter was used for the
transgene and a T7 promoter was used for expression of the
selectable marker. The two promoters, for transgene and
selectable marker, were placed back-to-back adjacent to each
other. The choice of a T7 promoter required the background cell
line to express T7 RNAP in addition to TetR. However, the use of
the T7 promoter had one important advantage, namely that as
transcription relies solely on the recognition of the 17 bp promoter
by the T7 RNAP, no transcription factors are required. Thus, the
footprint of the promoter on the chromatin is small and unlikely to
overlap with the footprint of the adjacent transgene promoter. At
the time, a second reason cited was that the strong transcription
from the T7 promoter ensured that the selectable marker gene was
expressed at high levels [2]. Low expression of the selectable
marker had been perceived as a possible problem with the first
generation vectors [7]. pLEW100 and its derivatives are successful,
widely used and available in many flavours [8] (http://tryps.
rockefeller.edu/trypsru2_plasmids.html).
The pLEW100 derivatives described above were all targeted to
the non-transcribed spacer within the repeat that contains the
rRNA genes. There are multiple rRNA loci located on several
chromosomes in the T. brucei genome and there is evidence that
there is variability in background expression and inducibility in
different rRNA loci [7][3]. This problem has been resolved by
placing a plasmid targeting sequence containing an incomplete
selectable marker gene in one selected rRNA locus [3]. The
construct containing the tetracycline-inducible transgene contains
a sequence sufficient to reconstitute the selectable marker gene and
thus ensures that integration occurs in the desired site.
Subsequent plasmids moved away from dependence on T7
RNAP by replacing the T7 promoter with an rRNA promoter [8]
thus removing the need to use a cell line expressing T7 RNAP.
The arrangement was similar to pLEW100 with adjacent back-to-
back promoters, a tetracycline-inducible transgene promoter and
an rRNA promoter driving expression of the selectable marker.
These vectors, the pDEX377 series, were designed to integrate in
the 177 bp repeats located on minichromosomes. This location
was chosen as it results in a lower level of background expression
of the transgene in the absence of tetracycline [9]. However, over a
couple of years of using pDEX377 derivatives to express
transgenes encoding proteins fused to various fluorescent proteins,
it is emerging that cells in clonal populations are prone to
unreliability, in that expression was markedly variable from one
cell to another (data showing this variability is included in the
results below).
All the plasmids described above require trypanosome cell lines
that express TetR and most also require T7 RNAP expression.
The most commonly used procyclic cell line, Lister 427 29-13,
contains two integrated plasmids: pLEW13 directing expression of
T7 RNAP and TetR using endogenous transcription within the
tubulin locus, and pLEW29 integrated into the RNA polymerase I
locus and directing TetR expression from a 10% activity T7
promoter [2]. There are several bloodstream form cell lines in
common use: Lister 427 13-90 contains integrated copies of
pLEW13 described above and pLEW90 in the tubulin locus,
directing TetR expression from a 10% activity T7 promoter [2].
Lister 427 ‘single marker line’ contains both T7 RNAP and TetR
genes integrated into the tubulin locus: the T7 RNAP is
transcribed by the endogenous polymerase and TetR by
expression from a 10% activity T7 promoter [2]. Lister 427
1313-1333 contains an integrated copy of pHD1313 placing two
TetR genes into the tubulin locus that are expressed through
endogenous transcription, and pHD1333 placing a T7 RNAP
gene under the control of a tetracycline-regulated promoter in the
non-transcribed spacer of the rRNA gene locus [10].
The expression system described here provides an alternative
approach to those above. The system has two advantages: it is
independent of T7 RNAP and can be readily introduced into
existing procyclic form cell lines. Integration of the plasmid
pSPR2.1 results in TetR expression with little clonal variation in
levels. The remaining plasmids, p3227 for transgene expression
and p3666 for double stranded RNA expression, use the
tetracycline-inducible EP1 procyclin promoter for regulated
expression and an rRNA promoter for selectable marker gene
expression.
Results
pSPR2.1, a plasmid for TetR expression in procyclic cell
lines
pSPR2.1 was designed for use with procyclic forms and was
constructed to integrate into the EP1-1 procyclin locus so that TetR
is transcribed by RNA polymerase I from the EP1 promoter
(Figure 1A). The expression of TetR in Lister 427 29-13
(abbreviated to 29-13 cell line) was compared with four
independent clones of the Lister 427 after integration of pSPR2.1
(abbreviated to SPR2.1 cell line) (Figure 1B). The expression of
TetR protein was significantly higher in all four clones of the
SPR2.1 cell lines than in the 29-13 cell line and the expression in
four clonal SPR2.1 cell lines was similar. This consistency in
expression levels means that pSPR2.1 can be used to modify
existing cell lines to obtain reliable expression of TetR.
One SPR2.1 cell line, clone MC3 (Figure 1B), was used for all
experiments from this point onwards. There was no obvious
morphological phenotype arising from integration of pSPR2.1 and
the growth was identical to the parental line (data not shown). The
growth of the SRP2.1 cell line was significantly faster than the 29-
13 cell line, with a doubling time of ,9 hours compared to
,15 hours, but this difference is also present in the two parental
cell lines which have diverged over time in culture (Figure 1C).
p3227, a base plasmid for tetracycline inducible
expression
The objective was to make a T7 RNAP independent plasmid
for reliable inducible transgene expression without the tendency
towards cellular heterogeneity in expression levels displayed by
pDEX377. In p3227, the approach taken was to separate the two
promoters by locating the plasmid backbone between the
tetracycline-inducible transgene and selectable marker gene
(Figure 2A). In p3227, transgenes can be exchanged as HindIII
BamHI fragments, or using other restriction enzymes to produce
compatible ends. The selectable marker gene can be exchanged as
a NdeI BstBI fragment and the transgene promoter as a Acc65I
HindIII fragment (Figure 2A). In addition, p3227 can be modified
to express C-terminal fusion proteins using the same approach as
previously described [8].
p3227 is targeted to the non-transcribed spacer in the rRNA
locus after linearisation with NotI. Prior to choosing this site, initial
experiments had tested integration of a similar plasmid into
minichrosome 177 bp repeats, as used with pDEX377 and
derivatives [8]. However, unlike pDEX377, no transgene
expression was detected in the presence of tetracycline. It was
reasoned that the absence of expression might result from
chromatin silencing of the inducible promoter as the distance to
Inducible Expression in Trypanosomes
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large enough to permit the default silenced state. Two derivatives
of pDEX377 were made to test this idea. pDEX377 contains a
back-to-back arrangement of the tetracycline-inducible EP1
promoter and an rRNA promoter driving the selectable marker
gene [8]; in the two derivatives the promoters were separated by a
250 bp or 500 bp. The expression of an eYFP-NLS transgene was
determined in two independent clones of each of the plasmids in
the SPR2.1 cell line (Figure S1). The expression of eYFP-NLS
decreased as the size of the spacer increased, implying that the two
promoters need to be very close to each other to achieve maximal
expression when the plasmid is targeted to the 177 bp repeats.
The original aim of this work was to produce a T7 RNAP
independent expression system and as a consequence a T7
promoter was left in the base plasmid from which p3227 was
derived. To test p3227, expression of an eYFP-NLS transgene was
compared with existing expression plasmids and cell lines and to
enable this experiment the T7 promoter was deleted as a 30 bp
fragment from p3227 to make p4084; the plasmids are otherwise
identical. Two independent clones of each of the cell lines SPR2.1
p3227 and 29-13 p4084 were analysed for eYFP-NLS expression
using Western blotting with anti-GFP (Figure 2B). After the
addition of tetracycline, all four clones had similar kinetics of
transgene expression, with the eYFP-NLS detected after 4 hours,
and after 16 hours all clones expressed similar levels. The
induction characteristics of the SPR2.1 and 29-13 cell lines were
similar and p3227/p4084 was able to support inducible expression
in both cell lines.
p3227 was modified to express transgenes with a tag at the C-
terminus by adding a BglII BamHI fragment encoding different
fluorescent protein ORFs to the BamHI site [8]. p3227 was further
modified by the addition of an XhoI site adjacent to the HindIII
site making p3927. XhoI HindIII fragments encoding different
fluorescent protein ORFs were then inserted between the XhoI
HindIII sites in order to express N-terminal fusion proteins. This
system of vector modification is the same as used with pLEW100
and pDEX377 earlier [8]. The N and C-terminal tagging plasmids
constructed so far are listed in Table S1.
Transgene expression at the single cell level
The intercellular variability in expression of an eYFP-NLS
transgene was compared between the plasmids p4084 (a derivative
of p3227), p4302 (a derivative of pLEW100) and p3467 (a
derivative of pDEX377). Each plasmid was integrated into the 29-
13 cell line and p4084 and p3467 were also integrated into the
SPR2.1 cell line. p4302 could not be used with the SPR2.1 cell line
as it requires T7 RNAP. Two independent clones of each cell line
and plasmid combination were analysed by flow cytometry
16 hours after tetracycline induction (Figure 2C). A ,350 fold
induction of transgene expression from the pLEW100 based
plasmid in the 29-13 cells was observed; moreover, expression was
relatively uniform and there were only a few cells with an
Figure 1. Comparison of the Lister 427 pSPR2.1 and Lister 427 29-13 cell lines. (A) Diagram showing pSPR2.1 and its integration after
digestion with SacI. The plasmid integrates between the EP1-1 ORF and promoter. The protein coding regions are represented by the large
rectangles. The intergenic regions are represented by the small rectangles and the origins of these regions are labelled above them. (B) Western blot
probed with anti-TetR and anti-PFR (loading control) showing the levels of TetR expression in wild type, 29-13, and four independent SPR2.1 cell lines.
(C) Comparison of growth of an SPR2.1 cell line and 29-13 cell line.
doi:10.1371/journal.pone.0035167.g001
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PLoS ONE | www.plosone.org 3 April 2012 | Volume 7 | Issue 4 | e35167Figure 2. p3227 supports tetracycline inducible expression. (A) Diagram of p3227 and its integration into the non-transcribed spacer in a
tandem array of rRNA genes after digestion with NotI. The other unique restriction sites shown allow the replacement of the promoter, transgene and
selectable marker. (B) Western blot probed with anti-GFP and anti-BiP (loading control) showing eYFP-NLS expression during a time course after
induction in SPR2.1 and 29-13 cell lines. (C) Flow cytometry measurement of eYFP-NLS levels in individual cells from representative clones in which
the different plasmids were induced with tet (green line) or without (black line) for 18 hours.
doi:10.1371/journal.pone.0035167.g002
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induced from the pDEX377 based plasmid in 29-13 cells a ,100
fold induction was seen with a substantial proportion of cells not
fluorescent or expressing an intermediate level of eYFP-NLS. For
the p3227 based plasmid in 29-13 cells, there was ,250 fold
induction of transgene expression with substantially smaller
number of cells expressing an intermediate level of fluorescence
than compared to the pDEX377 based plasmid.
The variability in expression of eYFP-NLS was compared
between the p3227 and p3467 in the SPR2.1 cell line (Figure 2C).
A ,350 fold induction of transgene expression was observed from
p3227, whereas p3467 only achieved ,150 fold induction with a
greater number of cells not expressing the inducible transgene at
all. A higher maximal expression level of eYFP-NLS was observed
in the SPR2.1 cells than the 29-13 cells; however, there was a
greater range of expression levels.
Plasmid for inducible stem loop expression for RNAi
A perceived problem with inducible RNAi vectors is incomplete
repression in the absence of tetracycline. An initial experiment was
performed to determine whether additional tetO sites would
reduce the levels of transgene expression in the absence of
tetracycline. p3227 was modified and two additional tetO sites
were introduced to make p3383. A comparison of the plasmids
p3227 and p3383 was performed by measuring eYFP-NLS
expression using flow cytometry in two independent clones of
each plasmid in the SPR2.1 cell line (Figure S2). The addition of
the extra tetO sites did not affect the level of eYFP-NLS present
without induction within the detection limit of the flow cytometer.
Importantly, the extra tetO sites did not affect expression levels of
the transgene after induction.
p3383 was used to construct p3666, which was designed to
express an RNA stem loop on tetracycline induction (Figure 3A).
Two changes were made to p3383: first the EP1 59 UTR,
including the splice acceptor site, was removed so trans-splicing
should not occur. Second, two stem multiple cloning sites
separated by a loop sequence replaced the transgene. The stem
multiple cloning sites (MCS) were designed for directional cloning
of fragments derived from the standard HindIII and BamHI
compatible fragments used in the expression vectors described
here and previously [8]. Both MCS can accommodate HindIII
compatible to blunt, blunt to BamHI compatible or HindIII
compatible to BamHI compatible fragments so that they have
opposite orientations and produce a stem loop on expression. This
design permits the same target gene derived restriction enzyme
fragment to be used in two successive rounds of subcloning to
produce a stem loop RNAi plasmid.
RNAi against DRBD3
To test the efficacy of p3666 and the SPR2.1 cell line, a
knockdown of DRBD3 was performed. The phenotype of the
knockdown in procyclic forms has been well characterised and is
lethal [11]. DRBD3 was chosen, as it had previously proved
problematic to produce a stable cell line in 29-13 cells using an
RNAi plasmid against DRBD3 based on the p2T7-177 plasmid
[9].
The stem loop DRBD3 RNAi plasmid was integrated into the
SPR2.1 cell line containing one wild type DRBD3 allele and one
allele modified to express DRBD3 with an eYFP tag at the C-
terminus. Three clones were selected and analysed. The doubling
time of the three clones were:12.3 h, 11.9 h, and 10.9 h, this was
significantly longer than the parental SPR2.1 cell line at 9.3 h
(Figure 1C). The difference could have arisen from one or more of
the following: (i) the presence of the RNAi construct, (ii) the
presence of blasticidin, (iii) low level RNAi depletion of DRBD3
due to incomplete repression of the RNAi construct or traces of
tetracycline in the foetal bovine serum. It is not readily possible to
distinguish these possibilities but it is worth noting that there was
no depletion of DRBD3 protein detected prior to addition of
doxycycline in the SPR2.1 cell line (Figure 3C).
The results of tetracycline addition for one clone, which were
typical, are shown in Figure 3B and 3C. Induction of the RNAi
caused a large reduction in growth rate after 48 hours (Figure 3B).
The expression of DRBD3 and DRBD3-eYFP was analysed
during the time course by Western blotting using an antiserum
raised against DRBD3 (Figure 3C) [11] (a kind gift of Antonio
Este ´vez). There was a reduction in the expression of both DRBD3
and DRBD3-eYFP after 12 hours and at 40 hours the protein was
barely detectable. Before induction, the expression of DRBD3 and
DRBD3-eYFP in the RNAi cell line was similar to that observed in
the untransformed parental cell line, indicating that there was little
background transcription from the RNAi plasmid. The new
plasmid and cell line enabled an effective RNAi cell line against
DRBD3 to be made.
Use of the new plasmid in bloodstream form cells
The success of the DRBD3 RNAi led to a trial in bloodstream
form cells. However, pSPR2.1 was not used as it relies on
transcription from the endogenous procyclic form specific EP1
locus. To circumvent this problem, Lister 427 bloodstream form
(BSF) cells were modified by the insertion of pHD1313 [10] (a kind
gift of Christine Clayton) which directs the expression of TetR after
integration into the tubulin locus. A second potential problem was
the use of an EP1 procyclin promoter in BSFs and a comparison of
the EP1 promoter and an rRNA promoter was performed. p3859
was made by modifying p3227 by replacing the EP1 promoter
upstream of the tetO sites with the equivalent region from an rRNA
promoter. The plasmids p3227 and p3859 were integrated into the
BSF pHD1313 cell line and two independent clones were selected
for each plasmid. The inducible expression in the four clones was
analysed by Western blotting after 16 hours of tetracycline
induction (Figure 4A). All four clones expressed detectable amounts
of eYFP-NLS after tetracycline addition and there was no
significant difference in the levels of expression of eYFP-NLS
between the EP1 and rRNA promoters. The level of eYFP-NLS
expression, normalised against BiP expression, was ,6 fold lower in
BSFs with either promoter than in PCFs.
The DRBD3 stem loop RNAi plasmid was integrated into the
BSF pHD1313 cell line. The effect of DRBD3 RNAi has not
previously been analysed in BSF cells. Three clones containing the
DRBD3 RNAi plasmid were analysed. The results for one clone,
which were typical, are shown in Figure 4B and 4C. After
24 hours of tetracycline induction there was a significant reduction
in growth rate. The level of DRBD3 was analysed along the
induction time course by Western blotting. There was a reduction
in DRBD3 expression after 12 hours of induction and DRBD3
was not detectable after 48 hours. These results suggest that the
loss of DRBD3 in BSF cells is lethal as it is in PCF cells. The RNAi
system effectively knocked down DRBD3 after induction and also
the expression level of DRBD3 observed in uninduced DRBD3
RNAi cells was comparable to the expression observed in the
parental cell line, suggesting that there was little background
transcription from the RNAi plasmid.
Discussion
A Lister 427 procyclic form cell line was modified by integration
of pSPR2.1 into the EP1 procyclin locus to produce the SPR2.1
Inducible Expression in Trypanosomes
PLoS ONE | www.plosone.org 5 April 2012 | Volume 7 | Issue 4 | e35167Inducible Expression in Trypanosomes
PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e35167cell lines. The expression of TetR was higher in SPR2.1 cell lines
than in the 29-13 cell line and expression was consistent between
clones. The level and consistency of pSRP2.1-directed TetR
expression between clones means that the plasmid can be
integrated into existing cell lines to give reliable TetR expression.
The SPR2.1 cells grew faster than 29-13 cells; this provides
advantages such as allowing a more rapid selection of transformed
cells. Furthermore, when expressing proteins using a pLEW100
plasmid and 29-13 cells three selectable markers are required [2],
whereas using p3227 and SPR2.1 cells only two selectable markers
are required, thereby freeing a selectable marker for another use.
When proteins were expressed from pDEX377, variation in
levels between individual cells was observed. Such variation in
gene expression between cells within a clonal population is a
Figure 3. Effective reduction of DRBD3 expression by RNAi based on p3666. (A) Diagram of p3666, the integration into the genome after
NotI digestion is the same as shown for p3227 in Fig. 2A. The arrangement of the restriction sites within the stem multiple cloning sites (MCS) is
shown. (B) Growth of cells expressing DRBD3-eYFP with or without tetracycline addition. Experiment was repeated with three clones and a
representative growth curve is shown. Red line is with tet induction; blue is without tet induction. (C) Western blot probed with anti-DRBD3 of
samples collected over a time course after induction of RNAi. The levels of DRBD3 and DRBD3-eYFP expression were normalised against the BiP
loading control. Experiment was repeated with three clones and a representative Western blot and quantitation is shown.
doi:10.1371/journal.pone.0035167.g003
Figure 4. p3666-based RNAi in bloodstream form cells. (A) Western blot probed with anti-GFP showing levels of eYFP-NLS expression in cell
lines using either the EP promoter or the rRNA promoter. The expression of eYFP-NLS was normalised against the BiP loading control. Data for two
independent clones is shown. (B) Growth of DRBD3 RNAi cell line with or without tetracycline induction. Experiment was repeated with three clones
and a representative growth curve is shown. Red line is with induction; blue is without induction. (C) Western blot probed with anti-DRBD3 of
samples collected over a time course after addition of tetracycline. The levels of DRBD3 expression were normalised against the BiP loading control.
Experiment was repeated with three clones and a representative Western blot and quantitation is shown.
doi:10.1371/journal.pone.0035167.g004
Inducible Expression in Trypanosomes
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For successful transcription, a complex needs to be assembled on
the promoter. When the promoters are adjacent the assembly of
one transcription complex could sterically hinder the construction
of a second and create a possible source of noise, which may
provide an explanation for the variation in eYFP-NLS expression
observed from pDEX377. The plasmid p3227 was constructed
with the bacterial backbone between the two promoters, which
resulted in less variation in expression than pDEX377 but still
resulted in greater variation than pLEW100 derivatives. The
separation of the promoters did not completely eliminate the
intercellular variability in expression, indicating that this effect is
not solely due to the close proximity of the two promoters. In
contrast, pLEW100 uses a T7 promoter, which is small and only
requires T7 RNAP for transcription, possibly reducing any clash
between the two promoter complexes, and here pLEW100 had the
smallest range of reporter expression level.
When an earlier version of p3227, identical with the exception
of the targeting sequences, was integrated into the 177 bp repeats
characteristic of minichromosomes there was no expression of the
reporter, implying that the inducible promoter had undergone
chromatin silencing. The presence of the selective antibiotic in the
media requires the continual transcription of the resistance
marker, hence maintaining an open chromatin structure around
that promoter. When the selectable marker and inducible
promoters are adjacent it is possible that the open chromatin
structure necessary for transcription of the selectable marker
allows transcription from both. Conversely, if the promoters are
separated there will be no selection pressure to maintain an open
chromatin structure at the inducible promoter. Evidence for this
model was provided by the introduction of a 500 bp spacer
between the promoters of pDEX377 resulting in a large reduction
in the expression of the reporter. The non-transcribed rRNA gene
spacer is less repressed than the 177 bp repeats [9] and was
therefore able to support inducible expression from p3227.
However, changes in chromatin structure between the selectable
marker promoter and the inducible promoter may account for the
variation in expression observed from p3227.
A DRBD3 RNAi plasmid derived from p3666 was used with the
SPR2.1 cell line. As DRBD3 knockdown is lethal, it gave a read-
out of the leakiness of the new RNAi plasmid in the SPR2.1 cell
line. Integration of the stem loop RNAi construct targeted against
DRBD3 into the SPR2.1 cell line resulted in many clones,
suggesting that the higher expression of TetR in SPR2.1 cells was
successfully repressing the expression of the RNAi construct.
Moreover, prior to the addition of tetracycline, the abundance of
DRBD3 in the cell line containing the RNAi plasmid was similar
to the untransformed parental cell line. Induction of the RNAi
against DRBD3 gave a significant reduction in growth rate after
48 hours, coupled with a reduction in DRBD3 expression, which
was undetectable by 40 hours. The combination of the SPR2.1
cell line and a p3666-derived RNAi plasmid allowed the
production of a cell line with RNAi targeted against DRBD3 that
matched the previously reported phenotype [11], which had been
technically problematic when using the 29-13 cell line in
combination with the p2T7-177 RNAi plasmid.
The effectiveness of the p3227 plasmid for inducible transgene
expression and p3666 for inducible RNAi was examined in BSF
cells. In this case, pSPR2.1 was not used to express TetR, as the
plasmid integrates into the EP1 locus, which is repressed in BSF
cells. The BSF pHD1313 cell line was used to overcome this
problem as these cells express TetR from the tubulin locus. The
combination of the BSF pHD1313 cell line and p3227 allowed
inducible expression of eYFP-NLS and there was no protein
detected when the cells were uninduced, indicating that the
expression was tightly regulated. It is worth noting that the relative
expression of eYFP-NLS was lower in BSF cells than in PCF cells.
One potential cause of the difference in expression level between
BSF cells and PCF cells is the use of the EP1 promoter, which
could lead to a lower expression of protein in the BSF cells. This
idea was examined by modifying the p3227 plasmid so the EP1
promoter was replaced with rRNA promoter, which should not be
differentially regulated. However, there was no difference
observed in the level of eYFP-NLS expression between the EP1
or rRNA promoter.
The expression level of DRBD3 in the uninduced RNAi cell line
was similar to the parental cell line, suggesting that there was
minimal knock down in the absence of tetracycline. Despite the
lower levels of inducible protein expression achieved in BSF cells,
the induction of DRBD3 RNAi resulted in a rapid decrease in
DRBD3 protein expression with no detectable DRBD3 present
after 48 hours. The loss of DRBD3 resulted in a reduction in
growth rate. RNAi knockdown of DRBD3 had only been
previously analysed in PCF cells; a recent genome-wide RNAi
screen has also found a reduction in growth rate associated with
DRBD3 knock-down in BSF cells [12]. The new plasmid p3227
and its RNAi derivative are also effective in BSF cells.
Finally there are numerous ribosomal spacer regions, into which
p3227 could integrate and these integration sites may result in
different levels of transcription [3]. The next step in the
development of p3227 will be to ensure that the plasmid is
targeted to the same ribosomal locus each time.
Materials and Methods
Trypanosomes
The Trypanosoma brucei Lister 427 procyclic cells used for
production of the SPR2.1 cell line originated from KG’s lab [13].
The Lister 427 29-13 cell line was a kind gift of George Cross [2].
Trypanosoma brucei Lister 427 MITat 1.5 (118) bloodstream form
cells originated in MC’s lab [14]. Transgenic trypanosomes were
generated using standard procedures. All experiments were
performed with logarithmically growing trypanosomes.
Plasmids and cloning
Details of the plasmids constructed for this study are described
in Table S2 and the sequences are in Table S3. All plasmids are
available from the authors and the GCK files are available to
download from http://web.me.com/mc115/mclab/downloads.
html.
Flow Cytometry
Mid-log phase density cells (5610
6 cells/ml) were analysed with
and without tetracycline induction using a BD FACScan (BD
Biosciences) in the Department of Pathology, University of
Cambridge.
Western blots
Western blots were performed using standard protocols. The
origin of the antibodies was: TetR, Clontech; PFR, monoclonal
antibody L8C4; GFP, Invitrogen; BiP from Jay Bangs; DRBD3
Antonio Este ´vez. Detection was either by ECL or using the
Odyssey Infrared Imaging System (LI-COR). For quantification,
the Odyssey software was used. The background method used was
the average of a three pixel width line at the top and bottom of
each band subtracted from each pixel within the band. Unequal
loading was corrected by reprobing the blots for BiP.
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Figure S1 Expression of eYFP-NLS decreases as the
space between the promoters increases. Western blot
probed with anti-GFP. The levels of eYFP-NLS expression were
normalised against the BiP loading control. Two independent
clones of each plasmid were examined and the percentage of cells
fluorescent after induction is shown.
(TIF)
Figure S2 Flow cytometry analysis of Lister 427
pSPR2.1 p3227 and Lister 427 p3383. Two independent
clones of each cell line were analysed with the typical result
presented here. Red line untransformed Lister 427 pSPR2.1, black
line uninduced, green line 18 hours tet induction.
(TIF)
Table S1 Table describing inducible tagging plasmids produced.
(DOC)
Table S2 Table describing plasmids used in this study.
pLEW100 is described in Wirtz et al. [2]. p2948 and pDEX377
are described in Kelly et al. [8].
(DOC)
Table S3 DNA sequences of all the plasmids used in this study.
(TXT)
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